Last update 17 Dec 2024

Ticagrelor

Last update 17 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, Ticagrelor (JAN/USAN/INN), AR-C-126532

+ [12]

Target

P2Y12 receptor

Mechanism

P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Acute Ischemic StrokeIschemic Attack, TransientCoronary Artery Disease+ [6]

Inactive Indication

Anemia, Sickle CellAngina, StableAnterior Wall Myocardial Infarction+ [17]

Originator Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Active Organization

AstraZeneca Pharmaceuticals Co. Ltd.AstraZeneca KKAstraZeneca Pty Ltd.

+ [5]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

EU (03 Dec 2010),

Acute Coronary Syndrome

RegulationPriority Review (CN)

Structure

Molecular FormulaC23H28F2N6O4S

InChIKeyOEKWJQXRCDYSHL-FNOIDJSQSA-N

CAS Registry274693-27-5

583

Clinical Trials associated with Ticagrelor

NCT06714526 / Not yet recruitingNot ApplicableIIT

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection Vs Conventional Clopidogrel Therapy in Symptomatic Intracranial Atherosclerotic Disease: a Pilot Prospective, Randomized, Open-label, Blinded-endpoint (PROBE) Multi- Centre Study

Stroke is an important cause of death, disability, and memory problems in adults. The build-up of plaque in arteries inside the brain is known as "intracranial atherosclerotic disease" or "ICAD" for short, and can reduce blood flow in the brain. Clopidogrel is a medicine used to prevent strokes because it stops blood from clotting. However, there are some people who do not get as much benefit from Clopidogrel because of differences in their genes; they have a variation in a certain gene and their body is not able to properly process Clopidogrel. Another medication called Ticagrelor can benefit people who have this genetic variation. The study investigators will randomize patients who have had a stroke due to ICAD to receive genetic testing, or standard of care. The standard-of-care group will take Clopidogrel for 90 days. The genetic testing group will complete a genetic test to see if they can properly process Clopidogrel. Depending on the results of the genetic test, patients will either take Clopidogrel or Ticagrelor for 90 days. All patients will have a brain scan at baseline and 90 days to see if they had any new strokes. Patients will also complete tests and questionnaires about function and memory at baseline and 90 days. This study will be one of the first to see if it is feasible and safe to use genetic testing to help choose medications for patients who have had a stroke. This will help the study investigators design a larger study that can test if genetic testing in stroke patients reduces future stroke risk and improves health outcomes.

Start Date01 Jan 2025

Sponsor / Collaborator

Sunnybrook Health Sciences Centre

TCTR20241028002 / Not yet recruitingPhase 1

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Ticagrelor 90 mg Film-coated Tablets and Reference Product (BRILINTA) in Healthy Thai Volunteers under Fasting Conditions

Start Date16 Dec 2024

Sponsor / Collaborator-

NCT06653348 / Not yet recruitingPhase 2/3IIT

De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial

This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 3 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.

Start Date01 Dec 2024

Sponsor / Collaborator

Mazandaran University of Medical Sciences

100 Clinical Results associated with Ticagrelor

100 Translational Medicine associated with Ticagrelor

100 Patents (Medical) associated with Ticagrelor

3,708

Literatures (Medical) associated with Ticagrelor

01 Feb 2025·AMERICAN JOURNAL OF CARDIOLOGY

Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis

Article

Author: Ezenna, Chidubem ; Nanna, Michael G ; Ismayl, Mahmoud ; Goldsweig, Andrew M. ; Joseph, Meghna ; Goldsweig, Andrew M ; Krishna, Mrinal Murali ; Bangalore, Sripal ; Pereira, Vinicius ; Nanna, Michael G.

The present guidelines recommend dual antiplatelet therapy (DAPT) for 6 to 12 months after percutaneous coronary intervention (PCI), with recent trials assessing the safety and efficacy of shortening DAPT duration to ≤3 months. A systematic search of PubMed, Scopus, and Cochrane Central databases identified studies comparing short DAPT, followed by P2Y12i monotherapy (78% ticagrelor) versus standard 12-month DAPT in patients who underwent PCI with a drug-eluting stent. A total of 9 randomized controlled trials, including 42,770 patients (short DAPT n = 21,370, 49.96%), of whom 28,307 (66.18%) presented with acute coronary syndrome (ACS). Short DAPT significantly reduced net adverse clinical events (NACEs) (risk ratio [RR] 0.78, 95% confidence interval [CI] 0.67 to 0.91, p = 0.001, I² = 62%), major bleeding (RR 0.54, 95% CI 0.39 to 0.73, p <0.001, I² = 63%), and any bleeding (RR 0.55, 95% CI 0.43 to 0.72, p <0.001, I² = 77%) at 12 months compared with 1-year DAPT. No significant differences were observed in major adverse cardiovascular/cerebrovascular events, myocardial infarction, stroke, stent thrombosis, mortality, or revascularization. Ticagrelor monotherapy after short DAPT further reduced major adverse cardiovascular/cerebrovascular events (RR 0.85, 95% CI 0.73 to 0.99, p = 0.040, I² = 22%), NACE (RR 0.74, 95% CI 0.61 to 0.89, p = 0.001, I² = 68%), and major bleeding (RR 0.56, 95% CI 0.40 to 0.78, p <0.001, I² = 71%) compared with 1-year DAPT; however, the test for subgroup interaction (P_interaction >0.05) for clopidogrel subgroup was not significant. P2Y12i monotherapy reduced the risk of NACEs (RR 0.77, 95%CI 0.66 to 0.90, p = 0.001, I² = 52%, P_interaction = 0.58) and major bleeding (RR 0.44, 95%CI 0.35 to 0.55, p <0.001, I² = 0%, P_interaction <0.01) in the ACS cohort but not in the chronic coronary syndrome cohort. In conclusion, short DAPT for ≤3 months followed by P2Y12i monotherapy (particularly, ticagrelor) was associated with decreased NACEs and bleeding without differences in other outcomes and should be considered a favorable option in patients with either ACS or chronic coronary syndrome after PCI with a drug-eluting stent.

01 Feb 2025·JOURNAL OF PHARMACY PRACTICE

Temporal Effect of CYP3A4/5 Induction on Ticagrelor’s Pharmacodynamic Effects: A Case Series

Article

Author: Lacoste, Jordan L. ; Rockhold, Matthew R. ; Szymanski, Thomas W.

Ticagrelor is contraindicated in combination with cytochrome P450 3A4 and 3A5 enzyme (CYP3A4/5) inducers due to increased clearance, causing diminished antiplatelet effects. The emergent nature of acute coronary syndromes (ACS) may preclude scrutinization of home medications before P2Y12 inhibitor administration. The purpose of this case series is to establish the temporal impact of CYP3A4/5 enzyme induction on ticagrelor’s pharmacodynamic effect by utilizing VerifyNow platelet aggregation studies. This was a retrospective case series of three patients who were taking a CYP3A4/5-inducing medication and loaded with ticagrelor for ACS. The duration of ticagrelor’s antiplatelet effect was dramatically shortened in the presence of background CYP3A4/5 induction. The offset of antiplatelet effect, defined by platelet reactivity units (PRU), was 10-24 hours in the presence of CYP3A4/5 enzyme induction compared to the anticipated 36-48 hours. This was consistent across CYP3A4/5-inducing medications including carbamazepine, phenobarbital, and phenytoin. This study demonstrates rapid return of platelet function after a ticagrelor loading dose in the presence of CYP3A4/5-inducing medications. Monitoring of PRU every 6-12 hours with subsequent loading with clopidogrel or prasugrel should be considered. Larger scale studies are warranted to confirm these results.

01 Feb 2025·IJC Heart & Vasculature

Rationale and design of the STOP-IMH randomised trial: Safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhage

Article

Author: Yosofi, B ; Peeters, D A M ; van Royen, N ; Heestermans, A A C M ; Konijnenberg, L S F ; von Birgelen, C ; Damman, P ; Claessen, B E P M ; Nijveldt, R ; van Rees, J B ; van Geuns, R J M ; van den Oord, S C H ; Woelders, E C I

Background:

Ticagrelor monotherapy after 1-3 months of dual antiplatelet therapy (DAPT) has shown to be effective and safe after percutaneous coronary intervention (PCI), including in patients with an ST elevation myocardial infarction (STEMI). Direct omission of aspirin could further reduce bleeding complications and may reduce the incidence and expansion of intramyocardial haemorrhage (IMH), a frequent complication after revascularisation for a STEMI.

Methods:

This multicentre open label pilot study randomises 200 STEMI patients within 24 hours after primary PCI and before the first subsequent dose of aspirin to ticagrelor monotherapy or ticagrelor plus aspirin for twelve months. As IMH is more frequently observed after an anterior STEMI, IMH and infarct size will be determined with cardiac magnetic resonance (CMR) imaging in 60 anterior STEMI patients. In this subgroup, blood samples will be analysed for biochemical outcomes.

Results:

The primary safety endpoint consists of major adverse cardiac and cerebral events, and the primary efficacy endpoint is infarct size on CMR. Secondary efficacy endpoints consist of the incidence and extent of IMH determined by CMR, and of clinical bleeding events. Other endpoints include all-cause mortality and biochemical outcomes.

Conclusion:

The STOP-IMH pilot study compares ticagrelor monotherapy with ticagrelor plus aspirin directly after primary PCI in 200 STEMI patients. We aim to provide a signal of safety regarding ischemic events for the direct omission of aspirin after primary PCI, and to compare the infarct size by CMR between the two treatment strategies in the first week after primary PCI.

News (Medical) associated with Ticagrelor

07 Oct 2024

·medcitynews.com

AstraZeneca Expands Cardiovascular Disease Prospects, Paying $100M for Oral Way to Drug Lp(a) - MedCity News

While drugs are available that reduce levels of a lipoprotein (a), a protein associated with cardiovascular disease, no currently available therapies target this protein directly. Several companies are in various stages of clinical development with drugs that could tackle this protein, and AstraZeneca is paying $100 million to license a preclinical drug gives it a contender in the chase. AstraZeneca’s new cardiovascular asset comes from Hong Kong-based CSPC Pharmaceutical Group. Beyond the upfront payment, the pharmaceutical giant could pay out up to $1.92 billion if the drug achieves development and commercialization milestones, according to deal terms announced Monday. CSPC will also receive royalties from sales of a commercialized product. The CSPC drug, named YS2302018, is in development for dyslipidemia, which is abnormally high levels of cholesterol in the blood. One biological indicator of this condition is high levels of lipoprotein (a), or Lp(a), a type of protein that transports cholesterol through the blood. High Lp(a) levels increase the likelihood of cholesterol buildup in the walls of blood vessels and they are a known risk factor for cardiovascular disease, including coronary artery disease and stroke. presented by Sponsored Post The Promise of Value-Based Care and MedTech Innovation Monica Vajani, Executive Director for mHUB’s MedTech Accelerator, discusses how mHUB is helping innovators transition healthcare towards value-based care. By Monica Vajani - mHUB Lp(a) levels can already be reduced by therapies addressing PCSK9, a liver protein that regulates cholesterol. Studies of the approved PCSK9 inhibitors Repatha from Amgen, and Praluent from Regeneron Pharmaceuticals, showed reductions in Lp(a) levels. Novartis’s approved small interfering RNA (siRNA) therapy Leqvio takes a different approach by silencing the gene that produces PCSK9. That drug also reduces Lp(a). But these therapies do not address Lp(a) directly and they are all administered as injections. AstraZeneca describes CSPC’s YS2302018 as an oral Lp(a) disruptor. Compared to the available injectable therapies addressing PCSK9, the CSPC drug offers the convenience of once-daily oral dosing. That formulation gives AstraZeneca a way to catch up to and potentially compete with Eli Lilly in the treatment of dyslipidemia. Lilly’s muvalaplin is an oral small molecule disrupter of Lp(a) currently in Phase 2 testing. Lilly is also part of a group of companies developing siRNA therapies that reduce Lp(a) levels. The Indianapolis-based pharma giant’s lepodisiran earlier this year began a Phase 3 clinical trial in atherosclerotic cardiovascular disease. Amgen’s olpasiran is in Phase 3 testing in the same indication while Silence Therapeutics’ is preparing to enter pivotal testing with its Lp(a)-reducing drug candidate, zerlasiran. Pelacarsen, an Ionis Pharmaceuticals antisense oligonucleotide intended to reduce Lp(a) production, is in Phase 3 testing under a partnership with Novartis. AstraZeneca’s cardiovascular, renal, and metabolism drug lineup is anchored by the blockbuster products Farxiga (approved for type 2 diabetes, heart failure, and chronic kidney disease) and Brilinta (approved for coronary acute syndromes). The company says the CSPC drug has potential uses in a range of cardiovascular disease indications as a standalone treatment or in combination with other therapies. presented by Health Tech What’s Keeping Healthcare CIOs Up at Night: How to Improve Patient Satisfaction by Handling Calls More Efficiently Health systems have spent billions on portals while investments in modernizing the voice channel — the dominant preference of healthcare consumers — have taken a backseat. By Stephanie Baum One potential combination could pair the CSPC drug with AstraZeneca’s own PCSK9 inhibitor, AZD0780. In May, the pharma giant reported Phase 1 results showing once-daily oral doses of AZD0780 on top of statin therapy led to a statistically significant 52% reduction in levels of LDL cholesterol. The drug was well tolerated and no serious adverse events were reported. AstraZeneca is currently testing the pill in a Phase 2 clinical trial with a targeted enrollment of 428 participants. “Given the scale of unmet need, with cardiovascular disease being a leading cause of death globally, advancing novel therapies that can be used alone or in combination to effectively address known risk factors and advance patient care is particularly important and a key part of our strategy,” Sharon Barr, AstraZeneca executive vice president and head of biopharmaceuticals R&D, said in a prepared statement.

Clinical ResultPhase 3Phase 2Drug ApprovalPhase 1

05 Aug 2024

·www.pharmaceutical-technology.com

FDA gives SFJ and SERB’s bentracimab BLA priority review

The BLA submission is grounded on the second interim analysis results of the Phase III REVERSE-IT trial. Credit: Michal Jarmoluk from Pixabay. The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) of SFJ Pharmaceuticals and SERB Pharmaceuticals’ bentracimab for filing and priority review. A human monoclonal antibody fragment, bentracimab is being developed as a reversal agent for ticagrelor, a medication used to reduce the risk of stroke or heart attack. SFJ Pharmaceuticals, sponsor of the bentracimab BLA, has partnered with SERB Pharmaceuticals, which has acquired exclusive US rights to the asset. SERB Pharmaceuticals is set to commercialise bentracimab in the US market, subject to approval. The FDA decision on the approval of bentracimab is anticipated in the first quarter (Q1) of 2025. See Also: FDA approves J&J’s multiple myeloma therapy Pharmaceutical Technology Excellence Awards 2024: SecureCHEK AI The BLA submission for bentracimab is grounded on the second interim analysis results of the Phase III REVERSE-IT trial. The first interim analysis of this trial was published in 2021. SFJ president and CEO Dr Barbara White stated: “Bentracimab has the potential to be an important medical advance if approved as the first and only specific reversal agent for ticagrelor, a P2Y12 platelet inhibitor. “We are confident that the data from the planned second interim analysis will support approval of bentracimab under priority review of the BLA.” Bentracimab is designed to counteract the antiplatelet effects of ticagrelor and its active metabolite in situations where reversal is necessary, such as nondeferrable surgery or invasive procedures, or in cases of major bleeding. SERB Pharmaceuticals CEO Vanessa Wolfeler said: “This milestone of BLA filing brings us closer to delivering a breakthrough therapy for patients and marks an important step in the next stage of growth for SERB. “The approval of bentracimab would offer US hospitals a much-needed solution to reverse the antiplatelet effects of ticagrelor and rapidly restore platelet function when needed.” The product received breakthrough therapy designation from the FDA in 2019, which accelerates the development and review process for treatments that show potential for significant improvement over existing therapies.

Priority ReviewPhase 3Breakthrough TherapyDrug ApprovalNDA

24 Jun 2024

·www.biospace.com

CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan

PRINCETON, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- CytoSorbents, Inc. (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the regulatory approval of CytoSorb® in Taiwan by the Taiwan Food and Drug Administration (TFDA). The approved indications include the extracorporeal removal of cytokines (e.g. cytokine storm, sepsis), bilirubin (e.g. liver disease), and myoglobin (e.g. trauma) from a patient’s circulating blood. The removal of the antithrombotic drugs Brilinta® (ticagrelor, AstraZeneca) and Xarelto® (rivaroxaban, Janssen/Bayer) during cardiothoracic surgery is also approved, with the goal of reducing perioperative bleeding. CytoSorb will be distributed throughout Taiwan by Hemoscien Corporation. Ms. Bettina Sabisch, Vice President of International Distributor Sales at CytoSorbents stated, “We are thrilled to announce this milestone which underscores the value and efficacy of our CytoSorb therapy and was achieved after navigating a long and complex approval process. We look forward to collaborating with Hemoscien and leveraging their long-standing customer relationships in Taiwan to bring this innovative therapy to patients in need.” Mr. Tom Juan, Managing Director of Hemoscien Corporation emphasized, “There is an ongoing critical need for more effective therapies to combat infections and to prevent or treat organ failure. I firmly believe that advanced blood purification devices such as CytoSorb® can complement the limitations of traditional pharmaceuticals by restoring peripheral blood homeostasis and balance. Given the widespread and successful application of CytoSorb therapy in numerous countries to treat life-threatening critical illnesses, we are confident in our ability to take what has been learned and to market and support CytoSorb in Taiwan's ICU sectors through our deep critical care network to help save the lives of severely ill patients.” In addition to Taiwan, CytoSorb is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses such as sepsis and septic shock, trauma, acute respiratory distress syndrome, burn injury, pancreatitis, and others that can lead to massive inflammation, organ failure and patient death. CytoSorb is also used as an extracorporeal liver support therapy in acute liver disease (e.g. acute on chronic liver failure, alcoholic hepatitis) and removes both liver toxins, such as bilirubin and bile acids, as well as cytokines. It is also used to treat rhabdomyolysis (e.g. trauma) and the removal of myoglobin. In these diseases, the risk of death can be extremely high, and there are few, if any, effective or practical treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. As of March 31, 2024, more than 237,000 CytoSorb devices have been used cumulatively around the world. Taiwan, with approximately 24 million inhabitants, offers universal coverage to its citizens through its National Health Insurance System and serves them through a network of nearly 400 medical centers and regional hospitals. With rising medical standards, use of advanced technology to increase administrative and provider efficiency, and access to high quality healthcare, Taiwan boasts one of the most progressive healthcare systems globally. Like many other parts of the world, critical illness including sepsis is a major problem in Taiwan. For example, there are 150,000 estimated new cases of sepsis reported each year in Taiwan with mortality rates as high as 30%, driven by diseases such as pneumonia, which is the third leading cause of death in Taiwan. About Hemoscien Corporation Hemoscien Corporation, a specialized hemo-epuration service provider, was established in 2008 as a spinoff from Smile Group Corp., originally founded in 1980. Since 1998, Hemoscien has maintained a strong partnership with Infomed S.A., a respected ICU hemo-therapy platform developer, achieving over 50% market share. The company is dedicated to its mission of addressing unmet medical needs in ICU care, as well as advancing regenerative medicine and other immune therapies. About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. CytoSorb, the Company’s flagship product, was originally launched in the European Union under CE mark as the first cytokine adsorber. In addition to the description in the text above, CytoSorb also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $50 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s websites at and or follow us on Facebook and X. Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, statements about potential exposures resulting from our cash positions, representations and contentions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. Please Click to Follow Us on Facebook and X U.S. Company Contact: Kathleen Bloch, CFO 305 College Road East Princeton, NJ 08540 +1 (732) 398-5429 kbloch@cytosorbents.com Investor Relations Contact: Eric Ribner LifeSci Advisors, LLC 250 W 55th St, #3401 New York, NY 10019 +1 (646) 751-4363 ir@cytosorbents.com

Drug Approval

100 Deals associated with Ticagrelor

External Link

KEGG	Wiki	ATC	Drug Bank
D09017	Ticagrelor	B01AC24	DB08816

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Ischemic Stroke	US	AstraZeneca Pharmaceuticals LP	05 Nov 2020
Ischemic Attack, Transient	US	AstraZeneca Pharmaceuticals LP	05 Nov 2020
Coronary Artery Disease	US	AstraZeneca Pharmaceuticals LP	28 May 2020
Myocardial Infarction	JP	AstraZeneca KK	28 Sep 2016
Angina, Unstable	AU	AstraZeneca Pty Ltd.	21 Jun 2011
Non-St Elevated Myocardial Infarction	AU	AstraZeneca Pty Ltd.	21 Jun 2011
ST Elevation Myocardial Infarction	AU	AstraZeneca Pty Ltd.	21 Jun 2011
Acute Coronary Syndrome	EU	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	IS	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	LI	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	NO	AstraZeneca AB	03 Dec 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary microvascular dysfunction	Phase 3	-	AstraZeneca PLC	15 Sep 2019
Diabetes Mellitus	Phase 3	-	AstraZeneca PLC	15 Sep 2019
Microvascular Angina	Phase 3	-	AstraZeneca PLC	15 Sep 2019
Anemia, Sickle Cell	Phase 3	US	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	BE	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	BR	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	EG	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	GH	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	GR	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	IN	AstraZeneca PLC	26 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02341729 (AGO/2013/011, Pubmed \| Acta Cardiol)	Phase 4	Heart Arrest platelet inhibition \| plasma concentrations of ticagrelor and its active metabolite	-	ticagrelor (Resuscitated cardiac arrest patients (STEMI/NSTEMI))	rsacatbpis(tmfjcvxjwm) = qqfyfwxzwp bynaqjgbbh (hyvygetrsr ) View more	Positive	08 Oct 2024
				ticagrelor (Semi-urgent CABG patients)	rsacatbpis(tmfjcvxjwm) = epzshnwils bynaqjgbbh (hyvygetrsr ) View more
ISAR-REACT5 (ESC2024)	Not Applicable	Acute Coronary Syndrome	-	Prasugrel	iaaodthxjt(ngrajarmkw) = anqabdisys refgehrlvh (rjvaqumhff )	Positive	02 Sep 2024
				Ticagrelor	iaaodthxjt(ngrajarmkw) = ddwdwyfnne refgehrlvh (rjvaqumhff )
ESC2024	Not Applicable	ST Elevation Myocardial Infarction	-	Cangrelor	tgmmpktxct(zrrbqzsrhx) = mqvgbxxigf ubckqyfxep (mparzzotqk, 3.4 - 7.2)	-	02 Sep 2024
				Standard therapy	tgmmpktxct(zrrbqzsrhx) = ipzbocvkfe ubckqyfxep (mparzzotqk, 5.2 - 8.5)
ESC2024	Not Applicable	platelet count	3,647	Ticagrelor	gqrxdytvbl(zxhshiicnp) = mwohnoackc fsineikdfi (cpujaoktvn ) View more	Negative	02 Sep 2024
				Clopidogrel	gqrxdytvbl(zxhshiicnp) = rtvcidjdyk fsineikdfi (cpujaoktvn ) View more
FAST-MI 2015 (ESC2024)	Not Applicable	Acute myocardial infarction	-	Ticagrelor	rgagftgtmy(kdqopykabk): HR = 0.61 (95% CI, 0.43 - 0.86), P-Value = 0.004 View more	Positive	01 Sep 2024
				Clopidogrel
ESC2024	Not Applicable	ST Elevation Myocardial Infarction	3,372	Ticagrelor	rbqbsieiwj(dxlwecnzgc) = iopddcxwxh haeaacakxx (hinkgtydrv ) View more	Positive	01 Sep 2024
				Clopidogrel	rbqbsieiwj(dxlwecnzgc) = qwanzvguxw haeaacakxx (hinkgtydrv ) View more
ESC2024	Not Applicable	Acute Coronary Syndrome	-	Standard dose ticagrelor	mbzzdfjbct(rclypvehkq) = upekhtukup vbuxpmgwxe (hfxdnrspfr ) View more	Positive	01 Sep 2024
				Reduced dose prasugrel	mbzzdfjbct(rclypvehkq) = fkvrwdppdw vbuxpmgwxe (hfxdnrspfr ) View more
ESC2024	Not Applicable	platelet count of 100~150×109/L	2,941	Ticagrelor	pdhocegjxa(ivpwxassin): aHR = 0.86 (95% CI, 0.6 - 1.23) View more	Negative	01 Sep 2024
				Clopidogrel
ESC2024	Not Applicable	Non-St Elevated Myocardial Infarction platelet count of 100~150×109/L	2,969	Ticagrelor	oslkrcdsua(fyxfqdhgzd): aHR = 0.84 (95% CI, 0.58 - 1.21) View more	Positive	31 Aug 2024
				Clopidogrel
ESC2024	Not Applicable	Coronary Disease	-	Clopidogrel	fhupxwqztq(dhvnnqdupq) = ltdjukgrgl witfypjugz (ucnamurinw )	-	30 Aug 2024
				Prasugrel or Ticagrelor	fhupxwqztq(dhvnnqdupq) = pdsujwcxjg witfypjugz (ucnamurinw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis